NO20025355L - Farmasöytisk preparat som omfatter en faktor VIIA og en faktor XIII - Google Patents

Farmasöytisk preparat som omfatter en faktor VIIA og en faktor XIII

Info

Publication number
NO20025355L
NO20025355L NO20025355A NO20025355A NO20025355L NO 20025355 L NO20025355 L NO 20025355L NO 20025355 A NO20025355 A NO 20025355A NO 20025355 A NO20025355 A NO 20025355A NO 20025355 L NO20025355 L NO 20025355L
Authority
NO
Norway
Prior art keywords
factor
pharmaceutical composition
xiii
viia
factor viia
Prior art date
Application number
NO20025355A
Other languages
English (en)
Norwegian (no)
Other versions
NO20025355D0 (no
Inventor
Lars Christian Petersen
Ulla Hedner
Rasmus Roejkjaer
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO20025355D0 publication Critical patent/NO20025355D0/no
Publication of NO20025355L publication Critical patent/NO20025355L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
NO20025355A 2000-05-10 2002-11-08 Farmasöytisk preparat som omfatter en faktor VIIA og en faktor XIII NO20025355L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200000771 2000-05-10
DKPA200000778 2000-05-10
DKPA200000871 2000-06-06
PCT/DK2001/000322 WO2001085198A1 (en) 2000-05-10 2001-05-10 tHARMACEUTICAL COMPOSITION COMPRISING A FACTOR VIIA AND A FACTOR XIII

Publications (2)

Publication Number Publication Date
NO20025355D0 NO20025355D0 (no) 2002-11-08
NO20025355L true NO20025355L (no) 2003-01-09

Family

ID=27222387

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20025355A NO20025355L (no) 2000-05-10 2002-11-08 Farmasöytisk preparat som omfatter en faktor VIIA og en faktor XIII

Country Status (17)

Country Link
US (3) US20030092627A1 (de)
EP (3) EP1593389A1 (de)
JP (2) JP2004505016A (de)
CN (1) CN1304049C (de)
AT (2) ATE300953T1 (de)
AU (3) AU5822801A (de)
BR (1) BR0110659A (de)
CA (1) CA2406583A1 (de)
CZ (1) CZ20023667A3 (de)
DE (2) DE60115422T2 (de)
DK (1) DK1282438T3 (de)
ES (2) ES2247106T3 (de)
HU (1) HUP0301868A3 (de)
IL (1) IL152554A0 (de)
NO (1) NO20025355L (de)
PL (1) PL365042A1 (de)
WO (2) WO2001085199A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20021186A3 (cs) * 1999-10-04 2002-11-13 Chiron Corporation Farmaceutické prostředky obsahující stabilizovaný kapalný polypeptid
US6905683B2 (en) 2000-05-03 2005-06-14 Novo Nordisk Healthcare A/G Human coagulation factor VII variants
US7015194B2 (en) 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
MXPA03001984A (es) 2000-09-13 2003-08-29 Novo Nordisk Healthcare Ag Variantes de factor vii de coagulacion humano.
WO2002022776A2 (en) * 2000-09-13 2002-03-21 Novo Nordisk A/S Human coagulation factor vii variants
JP2004512374A (ja) * 2000-11-03 2004-04-22 ザイモジェネティクス，インコーポレイティド Ａ型血友病の治療のための第ｘｉｉｉ血液凝固因子の使用
WO2002038162A1 (en) 2000-11-09 2002-05-16 The Scripps Research Institute MODIFIED FACTOR VIIa
JP2004513150A (ja) * 2000-11-10 2004-04-30 ザイモジェネティクス，インコーポレイティド Ｂ型血友病の治療方法
BR0207007A (pt) * 2001-02-05 2004-02-17 Novo Nordisk Healthcare Ag Composição farmcêutica, kit, usos de uma preparação e de uma composição, e, métodos para tratar de episódios de hemorragia em um paciente, para reduzir o tempo de coagulação em um paciente, para intensificar a hemostasia em um paciente para reduzir o número de administrações da proteìna do fator de coagulação necessário para deter a hemorragia e manter a hemostasia em um paciente, para reduzir a quantidade de proteìna do fator de coagulação administrada necessária para deter a hemorragia e manter a hemostasia em um paciente, para prolongar o tempo de lise do coágulo em um paciente, para aumentar a resistência do coágulo em paciente e para intensificar a formação de coágulo de fibrina em um paciente
EP1379271A1 (de) * 2001-02-21 2004-01-14 ZymoGenetics, Inc. Therapie des von willebrand syndroms
EP1425034A4 (de) * 2001-09-10 2005-09-21 Zymogenetics Inc Verfahren zur behandlung von durch cumarin induzierten blutungen
US7052868B2 (en) 2001-09-27 2006-05-30 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
US6960657B2 (en) 2001-11-02 2005-11-01 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
WO2003039581A1 (en) * 2001-11-09 2003-05-15 Novo Nordisk Health Care Ag Pharmaceutical composition comprising factor vii polypeptides and tranexamic acid
US20030119723A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and PAI-1 polypeptides
US7291587B2 (en) 2001-11-09 2007-11-06 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and TAFI polypeptides
JP2006510568A (ja) * 2001-11-09 2006-03-30 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子ポリペプチドおよびイプシロン―アミノカプロン酸を含む薬学的組成物
EP1458408B1 (de) * 2001-12-21 2009-04-15 Novo Nordisk Health Care AG Flüssige zusammensetzung aus faktor vii polypeptiden
CN101675991A (zh) * 2001-12-21 2010-03-24 诺和诺德医疗保健公司 因子ⅶ多肽的液体组合物
CN1671410B (zh) 2002-06-21 2010-05-12 诺和诺德医疗保健公司 因子ⅶ多肽的稳定化固体组合物
US6911323B2 (en) 2002-09-25 2005-06-28 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
DE602004019761D1 (de) * 2003-01-08 2009-04-16 Novartis Vaccines & Diagnostic Stabilisierte wässrige zusammensetzungen mit gewebefaktorinhibitor (tfpi) oder gewebefaktorinhibitor-variante
EP1641487B1 (de) 2003-06-25 2012-02-29 Novo Nordisk Health Care AG Flüssige zusammensetzungen von factor vii polypeptiden
JP5653572B2 (ja) 2003-08-14 2015-01-14 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドの液状水性医薬組成物
ES2381110T3 (es) 2003-09-09 2012-05-23 Novo Nordisk Health Care Ag Polipéptidos de factor VII de coagulación
WO2005107795A1 (en) * 2004-05-11 2005-11-17 Novo Nordisk Health Care Ag Use of factor viia for the treatment of burn traumas
WO2005115442A1 (en) * 2004-05-25 2005-12-08 Novo Nordisk Health Care Ag Use of coagulation factor xiii for treatment of post surgical bleedings
CN101010333B (zh) * 2004-08-27 2013-08-14 诺和诺德医疗保健公司 从生物材料中纯化凝血因子xⅲ多肽
EP1791555B1 (de) * 2004-09-10 2013-03-13 Pharmaorigin ApS Verfahren zur Behandlung von lokalen trachealen, bronchialen oder alveolären Blutungen oder Hämoptyse
CA2587139C (en) 2004-11-23 2014-05-27 Zymogenetics, Inc. Purification of recombinant human factor xiii
EP1855712A2 (de) * 2005-02-28 2007-11-21 Novo Nordisk Health Care AG Fxiii-varianten mit verbesserten eigenschaften
EP1919499A2 (de) * 2005-07-29 2008-05-14 Universiteit van Maastricht Regulierung von gewebefaktoraktivität durch proteine und tfpi (tissue factor pathway inhibitor)
US8461115B2 (en) 2006-03-16 2013-06-11 Stellaris Pharmaceuticals Aps Methods for local treatment with factor VII
WO2008009634A2 (en) * 2006-07-17 2008-01-24 Novo Nordisk Health Care Ag Factor viia analogues with increased activity for treating thrombocytopenia
CA2683443A1 (en) * 2007-04-13 2008-10-23 Catalyst Biosciences, Inc. Modified factor vii polypeptides and uses thereof
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
ES2640343T3 (es) 2008-04-21 2017-11-02 Novo Nordisk Health Care Ag Composición de transglutaminasa anhidra
EP2149603A1 (de) 2008-07-28 2010-02-03 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Faktor-IX-Varianten mit Gerinnungsaktivität in Abwesenheit ihres Cofaktors und ihre Verwendung zur Behandlung von Blutungsstörungen
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
KR101792032B1 (ko) 2008-12-19 2017-11-02 백스터 인터내셔널 인코포레이티드 Ｔｆｐｉ 억제제 및 사용 방법
DK2547355T3 (en) * 2010-03-19 2017-03-20 Baxalta GmbH TFPI INHIBITORS AND METHODS OF USE
CL2011001887A1 (es) * 2010-08-05 2012-02-03 Council Scient Ind Res Construcciones de proteinas quimericas que poseen propiedades anticoagulantes y tromboliticas; secuencia de acido nucleico que las codifica; vector; celula huesped; metodo de preparacion; formulacion farmaceutica que las comprende; y su uso para inhibir la trombina.
BR112014022435B1 (pt) 2012-03-21 2023-02-14 Takeda Pharmaceutical Company Limited Inibidores de tfpi e métodos de uso
EP2881463A1 (de) 2013-12-09 2015-06-10 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Faktor-IX-Varianten mit Gerinnungsaktivität in Abwesenheit ihres Cofaktors und/oder mit erhöhter F.IX-Gerinnungsaktivität und ihre Verwendung zur Behandlung von Blutungsstörungen
JP6559188B2 (ja) * 2017-07-06 2019-08-14 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
JP2018038398A (ja) * 2017-09-04 2018-03-15 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
JP2018108089A (ja) * 2018-02-19 2018-07-12 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
JP7444059B2 (ja) * 2018-07-25 2024-03-06 ソニーグループ株式会社 血液凝固系解析装置
JP6848016B2 (ja) * 2019-07-16 2021-03-24 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
EP3833381B1 (de) 2019-08-15 2022-08-03 Catalyst Biosciences, Inc. Modifizierte faktor-vii-polypeptide zur subkutanen verabreichung

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4221780A (en) * 1978-12-04 1980-09-09 Cort Joseph H Method for producing high potency factor VIII
AU593042B2 (en) * 1985-11-26 1990-02-01 Novo Nordisk Health Care Ag Compositions and methods for the treatment of bleeding disorders
US5622988A (en) * 1990-06-15 1997-04-22 Novo Nordisk A/S Use of a low molecular weight metabolite from fungus for reducing prolonged coagulation time
DK261490D0 (da) * 1990-10-31 1990-10-31 Novo Nordisk As New pharmaceutical compound
WO1993006855A1 (en) * 1991-10-11 1993-04-15 Novo Nordisk A/S Hemostatic composition for local hemostasis
CA2127107C (en) * 1991-12-31 2007-06-19 Bruce L. A. Carter Methods and compositions for reducing blood loss
EP0651655A4 (de) * 1992-07-24 1996-05-29 Oklahoma Med Res Found Blockierung der protein c aktivierung reduziert den blutverlust in mikrogefässen bei chirurgischen eingriffen.
DE4429118C2 (de) * 1994-08-17 1997-01-16 Siemens Ag Radarsensor
EP0885020A1 (de) * 1996-02-20 1998-12-23 Cohesion Corporation Verbindungen zum gewebeverschluss und methoden zu deren gebrauch
AU7907398A (en) * 1997-06-23 1999-01-04 Novo Nordisk A/S Use of fviia for the treatment of bleedings in patients with a normal blood clotting cascade and normal platelet function
AU2094199A (en) * 1997-12-23 1999-07-12 Nuvas Llc Thrombogenic polypeptide chimeras and conjugates having activity dependent upon association with tumor vascular endothelium
WO1999058699A2 (en) * 1998-05-14 1999-11-18 Battelle Memorial Institute Transgenic plant-derived human blood coagulation factors
EP1148427A1 (de) * 2000-04-21 2001-10-24 Koninklijke KPN N.V. Methode und System zur Erzeugung eines Lesezeichen-Knopfs in einem Web-Browser mit der Darstellung eines vom Benutzer ausgewählten Teils der zugehörigen Datei
US7015194B2 (en) * 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
US6825323B2 (en) * 2001-01-10 2004-11-30 The United States Of America As Represented By The Secretary Of The Army Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using same
BR0207007A (pt) * 2001-02-05 2004-02-17 Novo Nordisk Healthcare Ag Composição farmcêutica, kit, usos de uma preparação e de uma composição, e, métodos para tratar de episódios de hemorragia em um paciente, para reduzir o tempo de coagulação em um paciente, para intensificar a hemostasia em um paciente para reduzir o número de administrações da proteìna do fator de coagulação necessário para deter a hemorragia e manter a hemostasia em um paciente, para reduzir a quantidade de proteìna do fator de coagulação administrada necessária para deter a hemorragia e manter a hemostasia em um paciente, para prolongar o tempo de lise do coágulo em um paciente, para aumentar a resistência do coágulo em paciente e para intensificar a formação de coágulo de fibrina em um paciente
US20030203845A1 (en) * 2001-02-05 2003-10-30 Knudsen Jens Bjerre Combined use of factor VII polypeptides and factor IX polypeptides
US7419949B2 (en) * 2001-07-16 2008-09-02 Novo Noridsk Healthcare A/G Single-dose administration of factor VIIa
US20060025336A1 (en) * 2001-07-16 2006-02-02 Novo Nordisk A/S Pharmaceutical compositions comprising combinations of factor VII polypeptides and aprotinin polypeptides
US20030119741A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and aprotinin polypeptides
US20030040480A1 (en) * 2001-07-20 2003-02-27 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and factor XI polypeptides
US20030124118A1 (en) * 2001-11-27 2003-07-03 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and protein S inhibitors
WO2003039585A1 (en) * 2001-11-09 2003-05-15 Novo Nordisk Health Care Ag Pharmaceutical composition comprising factor vii polypeptides and protein c inhibitors
US20030119743A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and tissue plasminogen inhibitors
US7078479B2 (en) * 2001-11-09 2006-07-18 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and alpha2-antiplasmin polypeptides
US7125846B2 (en) * 2001-11-09 2006-10-24 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and factor V polypeptides
US7291587B2 (en) * 2001-11-09 2007-11-06 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and TAFI polypeptides
JP2005526004A (ja) * 2001-11-09 2005-09-02 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドおよびトラネキサム酸を含む薬学的組成物
US20030119723A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and PAI-1 polypeptides
JP2006510568A (ja) * 2001-11-09 2006-03-30 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子ポリペプチドおよびイプシロン―アミノカプロン酸を含む薬学的組成物

Also Published As

Publication number Publication date
US20060199766A1 (en) 2006-09-07
IL152554A0 (en) 2003-05-29
DK1282438T3 (da) 2005-11-14
HUP0301868A2 (hu) 2003-08-28
EP1282439A1 (de) 2003-02-12
NO20025355D0 (no) 2002-11-08
EP1282438B1 (de) 2005-08-03
ES2247106T3 (es) 2006-03-01
DE60112429T2 (de) 2006-06-01
DE60115422T2 (de) 2006-08-17
CZ20023667A3 (cs) 2003-04-16
EP1282438A1 (de) 2003-02-12
US20030092627A1 (en) 2003-05-15
JP2003532684A (ja) 2003-11-05
AU2001258230A1 (en) 2001-11-20
JP2004505016A (ja) 2004-02-19
WO2001085198A1 (en) 2001-11-15
EP1282439B1 (de) 2005-11-30
ATE300953T1 (de) 2005-08-15
WO2001085199A1 (en) 2001-11-15
BR0110659A (pt) 2003-02-11
CN1429117A (zh) 2003-07-09
AU2001258228B2 (en) 2006-01-12
ATE311198T1 (de) 2005-12-15
PL365042A1 (en) 2004-12-27
CA2406583A1 (en) 2001-11-15
HUP0301868A3 (en) 2006-11-28
ES2254414T3 (es) 2006-06-16
DE60115422D1 (de) 2006-01-05
DE60112429D1 (de) 2005-09-08
US20070280920A1 (en) 2007-12-06
CN1304049C (zh) 2007-03-14
EP1593389A1 (de) 2005-11-09
AU5822801A (en) 2001-11-20

Similar Documents

Publication Publication Date Title
NO20025355D0 (no) Farmasöytisk preparat som omfatter en faktor VIIa og en faktor XIII
SE0102315D0 (sv) Compounds
PT1313489E (pt) Composicoes farmaceuticas para o tratamento de mucosite, estomatite e sindroma de behcet
BR0211390A (pt) Tratamento de infecções da unha com no
NO20024528L (no) Proteaseinhibitor, farmasoytisk sammensetning og anvendelse av forbindelsen
NO20033566L (no) Acylerte 6,7,8,9-tetrehydro-5H-benzocykloheptenyl-aminer og deres anvendelse som farmasöytiske midler
NO20033100L (no) Uorganiske matrikssammensetninger og kompositter som inneholder matrikssammensetningen
ATE340844T1 (de) Stabile, wässerige zusammensetzungen zur behandlung von oberflächen , insbesondere geweben
DK1329456T3 (da) Glucopyranosyloxybenzylbenzenderivater og medicinske sammensætninger indeholdende samme
NO20005265L (no) Substituerte benzamider, deres fremstilling og anvendelse som inhibitorer av cystin-proteaser
DK1280500T3 (da) Synergistisk oral sammensætning mod plak og gingivitis
IS6741A (is) Samsetning til að gera tennur hvítar og aðferð sem notar díkarboxýlsýru sem hvítunarmiðil
DE60204584D1 (de) Zusammensetzungen enthaltend eine niedrige konzentration an peroxide zur behandlung von vaginitis
ITTO20010804A0 (it) Composizioni a base di aminoacidi, idonee alla terapia per la cicatrizzazione e/o riparazione di ferite e lesioni, in particolare per l'appl
EE05534B1 (et) IL-18 inhibiitorite kasutamine ravimi valmistamiseks kardiomopaatia raviks ja/v?i ennetamiseks
NO20032597L (no) Anvendelse av SARP-1 for behandlingen og/eller forebyggingen av skleroderma
NO20030998D0 (no) Arylpiperazinderivater og deres anvendelse som psykotropiske midler
DE60225446D1 (de) Flammgeschützte zusammensetzung und artikel
NO20014946L (no) Strukturerte multiformåls-pakkinger og deres anvendelse
BR0206087A (pt) Formulação de enxaguamento redutora para uso com ozÈnio no tratamento de cáries dentárias
FR2804320B1 (fr) Composition cosmetique favorisant la respiration cellulaire
AU2002210491A1 (en) Agent having prolonged stomach retention time used to produce a longlasting saturation effect, and the use thereof
DK1423429T3 (da) Antistoffer mod caspase-8 og deres fremstilling og anvendelse
MXPA03000780A (es) Derivados de acetamida y uso como inhibidores de los factores de coagulacion xa y viia.
SI1313489T1 (en) Pharmaceutical compositions for the treatment of mucositis, stomatitis and behcet's syndrome

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application